



## Umbilical Cord Stem Cell Stem Cell Therapy For Rare Genetic Disease Prader-Willi Syndrome

Deby Susanti Vinski\*, Natasha Cinta Vinski<sup>2</sup>  
*Cell Tech Stem Cell Centre Laboratory & Banking, Jakarta, Indonesia*

### Abstract

This abstract summarises the studies on the use of umbilical cord stem cells to treat Prader-Willi syndrome. Among the various stem cells found in the umbilical cord, hematopoietic and mesenchymal stem cells may create bioactive molecules that aid in tissue repair and regeneration, control immunological responses, and give birth to a variety of cell types. Because of this, they present a feasible option for treating the multidisciplinary character of PWS. Preclinical research on PWS animal models has shown promising outcomes, with umbilical cord stem cell transplantation improving metabolic disorders, hypothalamic function, and general behavior. It has been investigated if immunological regulation, trophic support, and paracrine signaling are among the factors that promote stem cell therapeutic potential. Several clinical studies employing umbilical cord stem cells to treat PWS are now underway, and the findings should aid in assessing the advantages and disadvantages of using this approach on patients. The preliminary evidence is encouraging, since some trial participants improved in hyperphagia, muscular tone, and cognitive ability. Although the use of umbilical cord stem cells as a PWS treatment has shown some promise, further study is required to determine its long-term safety, optimal dose, and ongoing effectiveness. A variety of key elements, such as ethical issues, regulatory frameworks, and the availability of standardized stem cell products, will have a considerable impact on the future development of this treatment technique. SD is a disease known as a neurodevelopmental problem represented through problems with social communication, sensor sensitivity, and repetitive behaviors. Despite years of study, therapy options for autism spectrum disorder (ASD) remain relatively limited. As regenerative medicine has improved, stem cell treatment has been investigated as a novel therapeutic option for the underlying neurological disorders that underpin ASD. The development, possible methods, and potential uses of stem cell treatment for autistic children are discussed in this article.

**Keywords:** Prader-Willi Syndrome, Umbilical Cord Stem Cells, Stem Cell Therapy, Genetic Disorder, Multi-Systemic Improvements, Preclinical Studies, Clinical Trials, Hypothalamic Function, Behavioral Manifestations.

### 1.Introduction Change

Prader-Willi Syndrome (PWS) patients and their families face a range of behavioral, mental, and physical issues as a result of the condition. Hypotonia, hyperphagia, developmental delays, and a proclivity towards obesity characterise PWS (Feraguti, et, al 2022). It was initially introduced in

1956 through Willi and Prader Labhart. It occurs due to the unavailability or the multifunctioning of paternally presented genes over chromosomes. The complicated interaction of genetic, neuroendocrine, and neurological variables that contribute to the various symptoms of PWS high-

---


Deby Susanti Vinski  
Cell Tech Stem Cell Centre Laboratory & Banking, Jakarta,  
Indonesia  
drdeby@eradunia.com

lights the need for novel treatment methods that go beyond standard kinds of therapy (Kamaludin, et, al , 2016 , 3798-3809). Traditional PWS treatments include nutritional and behavioural therapies, growth hormone therapy, and pharmaceutical interventions. However, they have not proven particularly effective in addressing all symptoms (Rahman, et, al , 2023, 5-12). Regenerative medicine research is becoming more crucial in order to address PWS at its base and provide more comprehensive and long-term treatment advantages. The use of stem cells derived from an infant's umbilical cord has gained interest as a kind of regenerative medicine due to the chance it provides for treating the root cause of hereditary illnesses rather than just their symptoms. The stem cells of umbilical cord have enough capability to develop into a wide amount of cells, govern immunological responses, and release bioactive substances that aid in tissue repair and regeneration. This distinguishes them as a possible solution to PWS's many problems (Stamm, et , al , 2022). The aim of this research is to offer an overview of the available body of knowledge on Prader-Willi syndrome treatment utilizing umbilical cord stem cells. The pathophysiology of PWS will be thoroughly discussed, as will the reasons why umbilical cord stem cells are a possible alternative treatment and the results of preclinical and clinical research that have examined the efficacy of

this unique strategy (Santos, 2023). In order to develop this promising science, we will also investigate ethical considerations, regulatory concerns, and possible future applications of umbilical cord stem cells in the treatment of PWS. Due to the limited effectiveness of current therapies, individuals with syndrome of Prader-Willi and their families have greater reason to be positive for the future as novel drugs such as umbilical cord stem cell therapy are investigated (Kamaludin, et, al , 2016 , 3798-3809). As our knowledge of the molecular processes at action and the advantages of stem cell-based methods grows, there is a better prospect of generating more effective and tailored PWS treatments.

### Syndrome of Prader-Willi Syndrome as a severe genetic disorder

Prader-Willi Syndrome (PWS) is a rare, severe genetic disorder that may cause a number of behavioural, mental, and physical difficulties (Liang, 2020).



**Figure 2:2 Dys-functioning as Prader-Willi Syndrome (G.Butler, et, al, 2016)**

### Historical background and genetic underpinnings

Prader, Labhart, and Willi discovered PWS for the first time in 1956. It's caused by problems with father-expressed genes on chromosomes (Stamm, et , al , 2022)

### Clinical Phenotypes of Various Types

The lack or faulty activity of particular genes causes a unique clinical appearance with symptoms such as diminished muscle tone, over-eating, delayed development, and a tendency to accumulate weight (Russo, 2015).



**Figure 1:Prader-Willi Syndrome as a severe genetic disorder (Butler, 2022)**



**Figure 3: Genetic Underpinnings**  
(Stamm, et , al , 2022)

**Problems with the way things are often done**

Although traditional interventions such as growth hormone therapy, dietary restrictions, and pharmacological therapies may be beneficial at times, they often fall short of treating the myriad PWS symptoms (Butler, et , al, 2019).

**The use of regenerative medicine is only getting started**

Because there is a need for comprehensive, long-term therapy that addresses the causes of PWS, regenerative medicine is gaining appeal.

**Umbilical cord stem cell therapy in a new region**

Stem cell treatment from the umbilical cord has sparked a lot of attention since it has the potential to

heal inherited diseases at their source and potentially change their trajectory (Butler, et , al, 2019).

**Characteristics of stem cells in the umbilical cord**

Stem cells derived from Umbilical cord are unique in their ability to differentiate, modify the immune system, and create useful molecules that help in tissue repair (Oztan, 2022)

**Goals of the Study**

The goal of this study is to offer a thorough picture of how PWS could be treated using umbilical cord stem cell treatment. This includes its biology, stem cell characteristics, experimental and clinical studies, ethical implications, legal and regulatory obstacles, and possible future uses (Butler, et , al, 2019).

**PWS Management Has New Hope**

Because current medications aren't very effective, researchers are looking into new techniques, like umbilical cord stem cell therapy, to assist individuals with PWS and their families enjoy better lives (Butler, 2022).

**Advance towards effective and targeted treatments**


The hope that we will be able to design treatments for PWS that are more efficient and tailored to each person grows as our knowledge of genetic mechanisms and the benefits of stem cells grows.

**Preclinical and Clinical studies**

Stem cell treatment has demonstrated promising effects in both early human studies and preclinical animal models, including improvements in social behaviors, language abilities, and cognitive function.


**Cell Types**

The Mesenchymal stem cells (MSCs) is initiated from bone marrow, adipose tissues, and umbilical cord as well as induced pluripotent stem cells (iPSCs), were investigated as possible therapies for autism (Rahman, et , al , 2023, 5-12). We looked at their characteristics, potential for distinction, and potential approaches for lowering autistic symptoms.



**Table 3**

**Figure 4: Characteristics of stem cells in Umbilical cord** (Vinski, 2023, 129-135)




**Figure 5: MSC cells (Stamm, et , al , 2022)**

## Material and Methods

For the convenience of the practicing physician or healthcare practitioner, we've produced a bulleted list of clinically concerned features and the components of genetic with Prader-Willi syndrome, and the diagnostic process including medical and treatment medical care plans (Soeda, et , al , 2019). The prevention strategies, screening, therapeutic option, and other options for individuals are for rare genetic issues linked to obesity were comprehensively assessed by a search of published research from the books, literature researches, and practice guidelines, including risk elements, key points, specific tests, consultation, laboratory/diagnostic element, and evaluation including patient satisfaction rate, priorities of lifestyle, complications and the instructions that need to be followed are just a few of the categories into which this information has been organized for easy searching during clinical care (Kamaludin, et, al , 2016 , 3798-3809).

## Limitations


There are a few things to take into mind in spite of the exciting potential that the umbilical cord stem cell therapy for Prader-Willi Syndrome (PWS) holds. Animal models are often



**Figure 6: Serotonin Transporter Genotype and Local Cohort (Russo, 2015)**

utilized in preclinical research, despite the fact that it is very improbable that they can accurately mimic the complexity of the human PWS (Rahman, et , al , 2023, 5-12). Predicting the efficacy of therapy is difficult due to the fact that animal habits might differ from person to person and that data may not be applicable to humans. Because there have been so few finished clinical trials and the follow-up periods have been so brief, we do not have sufficient information to determine whether or not the treatment is






**Figure 7: Graph presenting age and occurrence (G.Butler, et, al, 2016)**

safe and effective over the long term. In order to conduct research that is both ethical and open to public scrutiny, it is necessary to make use of cutting-edge technology and to give serious thought to the moral dilemmas that arise from stem cell therapy, such as the procedures for obtaining authorization (Russo, 2015). The use of stem cells as a therapeutic option for children diagnosed with ASD has revolutionary potential; nevertheless, this treatment option is limited by a number of important considerations. In spite of the promising results obtained from preclinical research and early-stage clinical trials, it is possible that the outcomes will be affected by the fact that ASD manifests in a variety of ways and that individuals respond differently to medications. In addition, as the mechanisms that are said to be responsible for the benefits become more understood, a more in-depth understanding of how stem cells use their advantages to their advantage develops (Oztan, 2022). The absence of a standardized methodology and an effective dose planning system creates complications whenever there is an effort made to compare and synthesize the results of numerous research inquiries. Because there is little data about the patient's long-term safety, especially in the context of stem cell therapy for pediatric populations, it is imperative that patients be continuously evaluated and tracked after receiving treatment. Concerns about patient autonomy, informed consent, and equitable access to treat-

ment are some of the ethical issues that need to be addressed as the clinical usage of stem cell therapy increases (Soeda, et, al, 2019). Even while the treatment of Prader-Willi illness using stem cells derived from umbilical cord tissue and the breakthrough stem cell therapy for children with autism spectrum disorder both provide promising paths of research, inherent limitations highlight the need for cautious interpretation and ongoing research. Strong study designs, significant data collection, stringent ethical frameworks, and coordinated efforts will be required in order to fully achieve the promise of stem cell therapy for these hard and complicated conditions (Vinski, 2023, 129-135).

## Results

Both animal and human studies show that stem cells harvested from umbilical cords might be used to treat Prader-Willi syndrome (PWS). Pre-clinical research using PWS animal models has shown promising results for the implantation of umbilical cord stem cells. These improvements included reductions in behavioral symptoms, normalization of hypothalamic function, and improvements in metabolic function. These stem cells have shown promise for a variety of systems due to their ability to promote neurogenesis, strengthen synaptic connections, and modulate hormone pathways (Rahman, et, al, 2023). Stem cell therapy is being considered as a potential game changer in the treatment of children having ASD, known as Autism Spectrum Disorder. While, induced pluripotent stem cells (iPSCs) and Mesenchymal stem cells (MSCs) are two forms of stem cells that have seen considerable advances in study. Stem cell treatment has been proven in preclinical research animal models to increase social behavior, cognitive abilities, and synaptic connections. The next critical issue is whether treating this hypoxia will have a favorable influence on autism. There is an increasing body of data linking hypoperfusion and the consequent hypoxia to autism. Hypoxia in autism is related with impaired function rather than apoptosis or necrosis in temporal neuron (Rahman, et, al, 2023, 5-12)s. Hypoperfusion, in addition to causing hypoxia, may also contribute to abnormalities by enabling metabolites or neu-



**Figure 8: Hypoxia to Autism (Russo, 2015)**

accumulate inappropriately. This is one of the reasons behind the present clinical study of Riluzole, a glutamate toxicity inhibitor, for the treatment of autism. In theory, after increasing circulation by stimulating angiogenesis, metabolite elimination and functional restoration should be possible. Children with autism may have cell loss in indefinite CNS locations. In this instance, neural progenitor cells would go through the cell cycle and eventually differentiate, assisting with brain regeneration. Neuronal regeneration has been shown in stroke, (Rahman, et al, 2023, 5-12) subarchinoidal hemorrhage, and brain injury caused by congenital metabolic abnormalities. In theory, restoring normal oxygen levels might trigger the body's self-healing processes. Other animal models of cerebral ischemia show similar neuronal growth following reperfusion. The potential benefits of hyperbaric oxygen therapy and other strategies for boosting oxygen levels in autistic people's brains are presently being explored in two separate clinical trials in the United States. To the best of our knowledge, cell therapy has seldom been employed to treat autism by increasing angiogenesis (Kamaludin, et al, 2016, 3798-3809).

### Discussion

The positive results of animal trials urge greater study into umbilical cord stem cell treatment for patients with PWS. The outcomes of early clinical studies on safety and feasibility give a glimpse into the prospective therapeutic advantages (Rahman, et al, 2023, 5-12). Some study participants reported improved mental performance, physical tone, and hyperphagia. These benefits are assumed to be the result of trophic factor production and paracrine signaling, the latter of which supports immune regulation and tissue healing.

Because of the complexities of PWS, a thorough approach is necessary. Umbilical cord stem cells have the ability to treat a variety of symptoms associated with the disease (Rahman, et al, 2023). Ethical difficulties, established methodology, the requirement for sufficient dosage, and long-term safety evaluations are just a few of the hurdles the sector must face. To traverse these hurdles and progress umbilical cord stem cell treatment as a possible breakthrough in the management of Prader-Willi Syndrome, researchers, medical experts, and regulatory agencies will need to work together indefinitely (Stamm, et al, 2022). Stem cell treatment has shown promise in addressing some of the most severe challenges connected with ASD in both animals and humans, according to research. Neurotrophic factor release, synaptic plasticity augmentation, and neuroinflammation management are emerging as major strategies for stem cell action (Kamaludin, et al, 2016, 3798-3809). Although the first results are promising, further study is required before these discoveries may be extensively applied in therapeutic operations. Larger, more thoroughly executed clinical trials are required to determine the safety, effectiveness, and long-term consequences of a medicine (Rahman, et al, 2023). Children with autism may benefit from stem cell treatment, but only if certain factors are taken into account. Patient screening, standardized methods, and the correct dose are only a few examples. The promise of stem cell therapy as a paradigm-shifting approach to autism treatment will not be realized without the coordinated efforts of researchers, physicians, and regulatory authorities (Oztan, 2022).

### Conclusion

The investigation of therapy known as stem cell therapy as a possible treatment for two unique and difficult disorders, Prader-Willi Syndrome (PWS) and Autism Spectrum Disorder (ASD), provides a promising but difficult environment. While research is still in its early phases, it seems that stem cells have enough capability to treat the complicated symptoms of a range of disorders. Preclinical and early clinical studies show that umbilical cord stem cell treatment may provide multi-systemic benefits to Parkinson's patients. The capacity to correct metabolic imbalances,

restore hypothalamic function, and alleviate behavioral issues demonstrates the therapeutic promise. However, barriers to successful adoption include ethical considerations, uniformity, and long-term safety evaluation (Oztan, 2022). Preclinical models and early-stage clinical trials using induced pluripotent stem cells and mesenchymal stem cells for treating ASD have shown promising results. Improved social relationships, cognitive capacities, and synaptic connections are just a few of the ways stem cells might help to address underlying faults. Nonetheless, the great variety of ASD presentations, the complexities of the underlying processes, and the necessity for extensive clinical trials all add to the cautious optimism around this revolutionary medicine (Butler, et al, 2019). As different stem cell treatment options emerge, the limits of each strategy highlight the necessity for in-depth study, multidisciplinary cooperation, and ethical awareness. The move from promising research to broad clinical application requires a consistent focus on security, openness, and patient welfare (Kamaludin, et al, 2016, 3798-3809). Although there are still challenges, the idea of radically changing the way Prader-Willi syndrome and autism spectrum disorder are handled gives people afflicted and their families hope. Stem cell therapy will need to be studied further and used with caution in order to reach its full potential and usher in a new age of treatment for these challenging and complex disorders. The pursuit of improvements in stem cell treatment is a critical first step in satisfying the unmet needs of persons suffering from the complex disorders Prader-Willi Syndrome (PWS) and Autism Spectrum Disorder (ASD) (Stamm, et al, 2022). Preliminary and current research into umbilical cord stem cell treatment for PWS shows some potential for a more comprehensive therapeutic approach. Despite being a promising avenue, treating metabolic dysregulation, recovering hypothalamic function, and reducing behavioural complexity would need overcoming ethical, regulatory, and technical obstacles to ensure safe and efficient clinical use. Similarly, advancements in stem cell treatment for children with ASD provide hope in the endeavour to better the lives of people impacted by this neurological disorder. Early accomplishments in preclinical models and early-phase clinical trials

indicate to a possible solution to the basic difficulties of ASD (Rahman, et al, 2023, 5-12). The complicated interaction of genetics, brain circuitry, and individual variability, on the other hand, need a full grasp of underlying processes and a careful extension of study. The difficulties of translating promising research into ground-breaking treatments are underscored in both cases by constraints such as the necessity for standardized methods, long-term safety evaluation, and comprehensive ethical concerns. Cooperation among researchers, physicians, regulatory authorities, and advocacy organisations will be required to overcome these challenges. Despite the challenges, the hunt for a breakthrough stem cell therapy for PWS and ASD has far-reaching ramifications (Oztan, 2022). It corresponds to the need for a more complete, effective, and all-encompassing strategy of addressing the complex symptoms and concerns that these diseases cause. Along the way, unwavering devotion, in-depth scientific inquiry, and a constant focus to the wellness and better quality of life of people impacted will be required. These pioneering approaches point to a future in which stem cell therapy might transform the treatment of uncommon genetic illnesses and neurodevelopmental difficulties.

## References

- Butler, M. G. (2022). Prader-Willi Syndrome. In *Neuroscience in the 21st Century: From Basic to Clinical* (pp. 3563-3603). Cham: Springer International Publishing.  
<https://doi.org/10.1007/978-3-030-98171-6>
- Butler, M. G., & Thompson, T. (2022). Clinical and Genetic Findings with Natural History of Prader-Willi Syndrome. In *Management of Prader-Willi Syndrome* (pp. 3-50). Cham: Springer International Publishing.  
<https://doi.org/10.3390/books978-3-0365-5026-8>
- Butler, M. G., Miller, J. L., & Forster, J. L. (2019). Prader-Willi syndrome-clinical genetics, diagnosis and treatment

- approaches: an update. Current pediatric reviews, 15(4), 207-244.  
<https://doi.org/10.2174/1573396315666190716120925>  
PMid:31333129 PMCID:P-MC7040524
- Ferraguti, G., Terracina, S., Micangeli, G., Lucarelli, M., Tarani, L., Ceccanti, M., ... & Fiore, M. (2022). NGF and BDNF in pediatrics syndromes. Neuroscience & Biobehavioral Reviews, 105015.  
<https://doi.org/10.1016/j.neubiorev.2022.105015>  
PMid:36563920
- G Butler, M., M Manzardo, A., & L Forster, J. (2016). Prader-Willi syndrome: clinical genetics and diagnostic aspects with treatment approaches. Current pediatric reviews, 12(2), 136-166.  
<https://doi.org/10.2174/1573396312666151123115250>  
PMid:26592417 PMCID:P-MC6742515
- Kamaludin, A. A., Smolarchuk, C., Bischof, J. M., Eggert, R., Greer, J. J., Ren, J., ... & Wevrick, R. (2016). Muscle dysfunction caused by loss of Magel2 in a mouse model of Prader-Willi and Schaaf-Yang syndromes. Human molecular genetics, 25(17), pp. 3798-3809.  
<https://doi.org/10.1093/hmg/ddw225>  
PMid:27436578
- Kandhari, R. (2021). Stem Cell Treatments in India: An Ethnography of Regular Practice. Medical Anthropology, 40(4), 348-360.  
<https://doi.org/10.1080/01459740.2020.1857379>  
PMid:33427512
- Liang, Y., Duan, L., Xu, X., Li, X., Liu, M., Chen, H., ... & Xia, J. (2020). Mesenchymal stem cell-derived exosomes for treatment of autism spectrum disorder. ACS Applied BioMaterials, 3(9), 6384-6.  
<https://doi.org/10.1021/acsabm.0c00831>  
PMid:35021769
- Oztan, O., Zyga, O., Stafford, D. E., & Parker, K. J. (2022). Linking oxytocin and arginine vasopressin signaling abnormalities to social behavior impairments in Prader-Willi syndrome. Neuroscience & Biobehavioral Reviews, 104870.  
<https://doi.org/10.1016/j.neubiorev.2022.104870>  
PMid:36113782
- Rahman, Q. F. A., Jufri, N. F., & Hamid, A. (2023). Hyperphagia in Prader-Willi syndrome with obesity: From development to pharmacological treatment. Intractable & Rare Diseases Research, 12(1), 5-12.  
<https://doi.org/10.5582/iridr.2022.01127>  
PMid:36873672 PMCID:P-MC9976092
- Rahman, Q. F. A., Jufri, N. F., & Hamid, A. (2023). Hyperphagia in Prader-Willi syndrome with obesity: From development to pharmacological treatment. Intractable & Rare Diseases Research, 12(1), 5-12.  
<https://doi.org/10.5582/iridr.2022.01127>  
PMid:36873672 PMCID:P-MC9976092
- Russo, F. B., Cugola, F. R., Fernandes, I. R., Pignatari, G. C., & Beltrão-Braga, P. C. (2015). Induced pluripotent stem cells for modeling neurological disorders. World journal of transplantation, 5(4), 209.  
<https://doi.org/10.5500/wjt.v5.i4.209>  
PMid:26722648 PMCID:P-MC4689931
- Santos, J. L. D. S., Araújo, C. D. A., Rocha, C. A.



G., Costa-Ferro, Z. S. M., & Souza, B. S. D. F. (2023). Modeling Autism Spectrum Disorders with Induced Pluripotent Stem Cell-Derived Brain Organoids. *Biomolecules*, 13(2), 260.  
<https://doi.org/10.3390/biom13020260>  
PMid:36830629 PMCID:P-MC9953447

Soeda, S., Saito, R., Fujita, N., Fukuta, K., & Taniura, H. (2019). Neuronal differentiation defects in induced pluripotent stem cells derived from a Prader-Willi syndrome patient. *Neuroscience Letters*, 703, 162-167.  
<https://doi.org/10.1016/j.neulet.2019.03.029>  
PMid:30902571

Stamm, S., & Butler, M. G. (2022). Molecular Genetic Findings in Prader-Willi Syndrome. In *Management of Prader-Willi Syndrome* (pp. 51-73). Cham: Springer International Publishing.  
[https://doi.org/10.1007/978-3-030-98171-6\\_2](https://doi.org/10.1007/978-3-030-98171-6_2)

Vinski, D. S. P., & Vinski, N. C. (2023). Mesenchymal Stem Cell Therapy for Prader-Willi Syndrome. *International Journal of Social Health*, 2(4), 129-135.  
<https://doi.org/10.58860/ijsh.v2i4.33>

